Trial
NCT00837824
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Genzyme, a Sanofi Company
Collaborators
CRL/Medinet
Condition
Fabry Disease
Intervention
Fabrazyme (agalsidase beta)
Why stopped
The trial was terminated early due to inadequate study design.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-04-07